Inhibition of Osteoclast Recruitment at a Local Site by 1-Hydroxyethylidene-1,1-Bisphosphonate (HEBP)

Adachi, Kristi; Chole, Richard A.

doi:10.1177/000348949009900914

Cited by 11 publications

(2 citation statements)

References 33 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bisphosphonates are stable analogues of pyrophosphate that have a strong affinity for bone hydroxyapatite. These agents inhibit bone resorption by reducing the recruitment and activity of osteoclasts and increasing apoptosis (16)(17)(18). Bone formed while patients are receiving bisphosphonate treatment is histologically normal (19).…”

Section: Bisphosphonatesmentioning

confidence: 99%

Update on osteoporosis therapy

Borges

Bilezikian

2006

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteoporosis is a skeletal disorder characterized by compromised bone strength that predisposes a person to increased fracture risk. Fractures are often associated with increased morbidity, higher mortality, loss of function and even psychological consequences. Pharmacotherapeutic interventions (e.g., bisphosphonates, selective estrogen receptor modulators, calcitonin, and teriparatide) in women with postmenopausal osteoporosis provide substantial reduction in fracture risk over and above risk reduction with calcium and vitamin D supplementation alone. The importance of nutritional support along with an appropriate exercise regimen, avoiding smoking and excessive alcohol use is to be emphasized along with the pharmacologic approach to osteoporosis. Despite the effectiveness of therapy with pharmacologic agents, most patients who start therapy do not remain on treatment for more than 1 year.

show abstract

Section: Bisphosphonatesmentioning

confidence: 99%

Update on osteoporosis therapy

Borges

Bilezikian

2006

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Implantable biodegradable wafers were prepared with ADP-loaded PLGA (75:25 mole ration by lactide to glycolide, molecular weight: 20,000 g/ mole) by direct compression method for the sustained release of ADP to investigate the possibility for the treatment of bone resorption. [92][93][94] The release pattern of ADP/PLGA wafers were observed by HPLC and the wafers were implanted the Mongolian gerbils mastoid. The release rate of APD increased with increase of its initial loading amount as shown in Figure 19.…”

Section: Of Processing Variable On Fentanyl Citrateloaded Plga Mss Bymentioning

confidence: 99%

Local drug delivery system using biodegradable polymers

Khang

Rhee

Jeong³

et al. 2003

Macromol. Res.

View full text Add to dashboard Cite

For last five years, we are developing the novel local drug delivery devices using biodegradable polymers, especially polylactide (PLA) and poly(D,L-lactide-co-glycolide) (PLGA) due to its relatively good biocompatibility, easily controlled biodegradability, good processability and only FDA approved synthetic degradable polymers. The relationship between various kinds of drug [water soluble small molecule drugs : gentamicin sulfate (GS), fentanyl citrate (FC), BCNU, azidothymidine (AZT), pamidronate (ADP), 1,25(OH) 2 vitamin D 3 , water insoluble small molecule drugs : fentanyl, ipriflavone (IP) and nifedipine, and water soluble large peptide molecule drug : nerve growth factor (NGF), and Japanese encephalitis virus (JEV)], different types of geometrical devices [microspheres (MSs), microcapsule, nanoparticle, wafers, pellet, beads, multiple-layered beads, implants, fiber, scaffolds, and films], and pharmacological activity are proposed and discussed for the application of pharmaceutics and tissue engineering. Also, local drug delivery devices proposed in this work are introduced in view of preparation method, drug release behavior, biocompatibility, pharmacological effect, and animal studies. In conclusion, we can control the drug release profiles varying with the preparation, formulation and geometrical parameters. Moreover, any types of drug were successfully applicable to achieve linear sustained release from short period (1~3 days) to long period (over 2 months). It is very important to design a suitable formulation for the wanting period of bioactive molecules loaded in biodegradable polymers for the local delivery of drug. The drug release is affected by many factors such as hydrophilicity of drug, electric charge of drug, drug loading amount, polymer molecular weight, the monomer composition, the size of implants, the applied fabrication techniques, and so on. It is well known that the commercialization of new drug needs a lot of cost of money (average: over 10 million US dollar per one drug) and time (average: above 9 years) whereas the development of DDS and high effective generic drug might be need relatively low investment with a short time period. Also, one core technology of DDS can be applicable to many drugs for the market needs. From these reasons, the DDS research on potent generic drugs might be suitable for less risk and high return.

show abstract

In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist

Chole

Faddis

Tinling

1995

Journal of Bone and Mineral Research

Self Cite

View full text Add to dashboard Cite

Interleukin-1 (IL-1) has been implicated as a primary mediator of bone remodeling; it is a powerful activator of bone resorption both in vivo and in vitro. However, there is no direct evidence that IL-1 plays a role in physiological bone modeling or remodeling. Interleukin-1 receptor antagonist (IL-1ra) is a member of the IL-1 family, which bind to IL-1 receptors and blocks the action of IL-1 alpha and IL-1 beta. We have previously shown that IL-1ra blocks IL-1-induced bone resorption in vitro. Evidence is reported here that human recombinant IL-1ra (hrIL-1ra) inhibits strain-induced modeling in the gerbil auditory bulla while having no significant effect on apposition rate. Pressurization of the auditory bulla to 10 mm Hg above atmospheric pressure increased osteoclast surface from 3.62 to 19.14%. Infusion of hrIL-1ra during pressurization resulted in significant inhibition of osteoclast surface on the pressurized side. These findings suggest that IL-1 is a physiological mediator of bone modeling and that hrIL-1ra inhibits resorption but not apposition in the auditory bulla model.

show abstract

Inhibition of Osteoclast Recruitment at a Local Site by 1-Hydroxyethylidene-1,1-Bisphosphonate (HEBP)

Cited by 11 publications

References 33 publications

Update on osteoporosis therapy

Update on osteoporosis therapy

Local drug delivery system using biodegradable polymers

In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist

Contact Info

Product

Resources

About